Background--We previously showed that the levels of both Gia-2 and Gia-3 proteins were augmented in spontaneously hypertensive rats (SHRs) before the onset of hypertension. In addition, intraperitoneal injection of pertussis toxin, which inactivates both Gia proteins, prevented the development of hypertension in SHRs. The aim of the present study was to determine the specific contributions of Gia-2 and Gia-3 proteins to the development of hypertension.
G
uanine nucleotide binding proteins (G proteins) are a large family of guanosine triphosphate binding proteins that play a crucial regulatory role as transducers in a variety of cell-signaling pathways. G proteins are heterotrimeric proteins composed of 3 distinct subunits; a, b, and c. All a subunits possess intrinsic GTPase activity and are responsible for specificity of receptor-effector interaction. 1 According to amino acid homology, G proteins are classified into 4 major subfamilies and are represented as Gsa, Gia, Gqa/a11, and Ga12/a13. G proteins exert their action via several signal transduction pathways including adenylyl cyclase and receptor-mediated activation of phospholipase C and A2. [2] [3] [4] The inhibition and stimulation of adenylyl cyclase is mediated via Gia and Gsa, respectively. Three distinct Gia forms (Gia-1, Gia-2, and Gia-3) are encoded by 3 different genes. All isoforms of Gia proteins inhibit adenylyl cyclase and activate atrial K + channels, 4, 5 whereas the 4 different isoforms of Gsa that were revealed by molecular cloning result from different splicing of 1 gene. Gsa is associated with adenylyl cyclase stimulation and increased cyclic AMP (cAMP) production. 6 Gia proteins and associated inhibition of adenylyl cyclase signaling have been shown to be implicated in a variety of cellular functions, including vascular permeability, 7, 8 salt and water transport, 9, 10 and catecholamine release, 11 all of which play key roles in the regulation of blood pressure (BP). Alteration in Gia protein levels is associated with impairment of cellular function that results in various pathological states including hypertension 12 and heart failure. 13, 14 Enhanced expression of Gia-2 and Gia-3 proteins and their genes was also shown in cardiovascular tissues from several animal models of hypertension including spontaneously hypertensive rats (SHRs), [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] whereas the levels of G 0 a and Gsa were not altered in hypertension. 15, 18, 19 Moreover, high salt intake in salt-sensitive hypertensive Dahl rats was shown to enhance expression of Gia proteins in heart failure, hypertension, and cardiac hypertrophy, 25 whereas central Gia-2 protein-gated pathways were reported to counter the development of saltsensitive hypertension. 26 Enhanced expression of Gia proteins and the Gi protein-mediated pathway in cardiovascular tissues and kidney was shown to contribute to the maintenance of hypertension in SHRs. 27, 28 In contrast, Gia-1 that is present predominantly in the brain and neural tissue and absent in heart and aorta 23, 29 does not appear to be implicated in the regulation of cardiovascular functions including BP in SHRs. The augmented expression of Gia proteins has been reported to occur before the onset of hypertension in SHRs and DOCA-salt hypertensive rats 30, 31 and suggests that the enhanced expression of Gia-2 and Gia-3 proteins is a factor contributing to the development of hypertension rather than a consequence of hypertension. This was further supported by our study showing that a single intraperitoneal injection of pertussis toxin, which inactivates both Gia-2 and Gia-3 proteins, prevented the development of hypertension in prehypertensive SHRs aged 2 weeks. 32 It is not clear whether the enhanced expression of Gia-2 or Gia-3 or both contributes to the development of hypertension in SHRs. The present study was undertaken to examine the specific contributions of Gia-2 and Gia-3 to the development of hypertension in SHRs by using an antisense oligodeoxynucleotide approach. Antisense oligodeoxynucleotide is composed of short fragments of single-strand DNA (13-25 nucleotides). The main concept underlying antisense therapy is simple: Use of a certain DNA sequence that is complementary to a specific mRNA will inhibit its transcription/gene expression and consequently inhibit protein synthesis. 33, 34 The antisense approach has been used extensively and successfully in hypertension research. Antisense targeting angiotensin receptor type 1, angiotensinogen, thyrotropinreleasing hormone, epidermal growth factor receptor, and insulin-like growth factor 1 receptor [35] [36] [37] [38] [39] attenuated BP in SHRs. Moreover, antisense targeting b-adrenergic receptor exhibited profound and prolonged reduction in BP. 40 Because antisense oligodeoxynucleotide is not serum stable and can be degraded easily by exonuclease and endonuclease, 41, 42 it was necessary to use the delivery system. The recent advancement in nanotechnology was positively reflected in the improvement of the liposomes as drug-delivery vectors. Liposome-based nanomedicines offer an interesting approach for delivery of gene therapeutic agents like antisense. This study provided evidence that knockdown of Gia-2 but not Gia-3 protein using antisense oligodeoxynucleotide encapsulated in PEG/DOTAP/DOPE cationic liposomes attenuated the development of hypertension and tachycardia and suggested that overexpression of Gia-2 but not Gia-3 protein plays an important role in tachycardia and the development of hypertension in SHRs.
Methods

Antisense Oligodeoxynucleotide
Antisense and the inverted-form sense oligomer targeting Gia-2 and Gia-3 proteins were purchased from Alpha DNA. These oligodeoxynucleotides were modified by phosphothioation of 3 nucleotides on both sides. The following sequences were used: Gia-2 antisense, 5 0 -C*T*T*GTCGATCATCTTA*G*A*3 0 ; Gia-3 antisense, 5 0 A*A*G*TTGCGGTCGATC*A*T*3 0 ; Gia-2 sense, 5 0 T*C*T*AAGATGATCGACA*A*G*3 0 ; and Gia-3 sense, 5 0 -A*T*G*ATC-GACCGCAAC*T*T*3 0 .
Liposomes
Cationic lipid DOTAP and helper lipid DOPE were purchased from Avanti Polar Lipids and mixed at a 1:1-M ratio. In addition, 10% DSPE-PEG(2000) (Avanti Polar Lipids) was incorporated in the lipid mixture to increase liposome stability, to prolong circulation time in the blood stream, and to prevent leakage and aggregation of liposomes, as described previously. 43 
Formulation of Lipoplexes
DOTAP, DOPE, and PEG were dissolved in chloroform. Dried lipid film was formulated by exposing the lipid mixture to a slow N 2 stream for evaporation of chloroform and then to a vacuum system overnight to ensure complete removal of chloroform traces. The lipid film was hydrated using sterile PBS with pH 7.4 at room temperature. The suspension was left at room temperature for 1 hour to allow assembly and formulation of liposomes. Liposomes were exposed to freeze/ thaw cycles (7-9 cycles) to facilitate size management using liquid nitrogen and warm tap water. The size was homogenized using manual graded extrusion with 800-, 400-, and 100-nm polycarbonate membranes (LiposoFast; Avestin, Inc). The final size of the liposomes was 100 to 200 nm with a polydispersity index of 0.1 measured using a dynamic light scattering technique (Malvern Zetasizer; Malvern Instruments). Antisense or sense of Gia-2 or Gia-3 was added to the final concentration of 200 lg/mL in sterile PBS with pH 7.4 and an N:P ratio of 2 calculated according to the Felgner equation. 44 Lipoplexes were left for 1 hour at room temperature to allow encapsulation of antisense or sense. To ensure that antisense was encapsulated inside the liposome, fluorescently labeled antisense was used.
Animals
Male SHRs aged 2 weeks and age-matched normotensive Wistar Kyoto (WKY) rats were purchased from Charles River Laboratories International, Inc. Animals were maintained at room temperature with free access to water and regular rat chow in 12-hour light/dark cycles. Rats were left for 1 week for adaptation. SHRs and WKY rats were divided into 6 groups (control, empty liposomes, Gia-2 antisense, Gia-2 sense, Gia-3 antisense, Gia-3 sense; 6-10 rats per group). Antisense or sense of Gia-2 or Gia-3 (1 mg/kg body weight) and empty liposomes were injected intravenously via tail vein once into prehypertensive SHRs aged 3 weeks and age-matched WKY rats. BP was monitored every week by the tail-cuff method without anesthesia, using the CODA standard noninvasive BP system (Kent Scientific Corp). After measurement of BP, heart rate, and body weight, groups of rats (WKY and SHRs with and without different treatments, as indicated above) aged 6 and 9 weeks were euthanized by decapitation after CO exposure. Thoracic aortas, hearts, and kidneys were removed by dissection and used for determination of Gia protein levels, oxidative stress, and other biochemical assays. All animal procedures used in the present study were approved by the Ethics Committee for experimentation on animals of the University of Montreal (approval 99050). The investigation conforms to the "Guide for the Care and Use of Laboratory Animals" published by the National Institutes of Health.
BP and Heart Rate Measurement
Rats were left for 1 week for adaptation. BP was measured weekly using the CODA noninvasive tail-cuff method, according to the recommendation of American Heart Association. 45 The CODA tail-cuff BP system uses volume pressure recording sensor technology to measure tail BP. Volume pressure recording is clinically validated and provides 99% correlation with telemetry and direct BP and heart rate measurements. BP was expressed as milligrams of mercury and heart rate as beats per minute.
Cell Culture
Aortic vascular smooth muscle cells (VSMCs) from SHRs aged 6 or 9 weeks and age-matched WKY rats (control group) and empty liposome-, sense-, and antisense-treated SHRs and WKY rats were cultured, as described previously. 30, 31 The purity of the cells was checked with an immunofluorescence technique using a-actin, as described previously. 46 These cells were found to contain high levels of smooth muscle-specific actin. The cells were plated in 75-cm 2 flasks and incubated at 37°C in 95% air and 5% CO 2 humidified atmosphere in DMEM (with glucose, Lglutamine, and sodium bicarbonate) containing antibiotics and 10% heat-inactivated FBS. Confluent cell cultures were starved by incubation for 3 hours in DMEM without FBS at 37°C to reduce the interference by growth factors present in the serum. The cell lysates were prepared and used for Western blotting and adenylyl cyclase activity determination.
Preparation of Heart, Aorta and Kidney Particulate Fraction
Heart, aorta, and kidney particulate fractions were prepared, as described previously. 18, 31 After rats were sacrificed, hearts, aortas, and kidneys were removed by dissection, quickly frozen in liquid nitrogen, and then pulverized into fine powder using a mortar and pestle precooled in liquid nitrogen. The powder was stored at À80°C until assayed. The powder was homogenized (12 strokes) in a glass homogenizer with a buffer containing 25 mmol/L Tris-HCl (pH 7.5), 25 mmol/L NaCl, 1 mmol/L sodium orthovanadate, 10 mmol/L sodium fluoride, 10 mmol/L sodium pyrophosphate, 2 mol/L benzamidine, 2 mmol/L ethylene-bis(oxy-ethylenenitrolo)tetraacetic acid, 2 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, 10 lg/mL aprotinin, 1% Triton X-100, 0.1% sodium dodecyl sulfate, and 0.5 lg/mL leupeptin. The homogenate was centrifuged at 12 000g for 15 minutes at 4°C. The supernatants were transferred to a fresh microcentrifuge tube without disturbing the pellet. Protein concentration was determined by Bradford assay. The supernatant was used for Western blotting.
Western Blotting
Western blotting of Gi proteins was performed using specific antibodies, as described previously. 20 After SDS-PAGE, the separated proteins were electrophoretically transferred to a nitrocellulose membrane with a semi-dry transfer blot apparatus (Bio-Rad Laboratories) at 15 V for 45 minutes. After transfer, the membranes were washed twice in PBS and were incubated in PBS containing 5% skim milk at room temperature for 1 hour. The blots were then incubated with the following specific antibodies: Gia-2 (L5), Gia-3 (C-10), and dynein (74-1; Santa Cruz Biotechnology) incubated in PBS containing 0.1% Tween 20 overnight at 4°C. The antigenantibody complexes were detected by incubating the blots with goat anti-rabbit immunoglobulin G (Bio-Rad Laboratories) conjugated with horseradish peroxidase for 1 hour at room temperature. The blots were then washed 3 times with PBS before reacting with enhanced chemiluminescence Western blotting detection reagents (Santa Cruz Biotechnology). Quantitative analysis of the protein was performed by densitometric scanning of the autoradiographs using the enhanced laser densitometer LKB Ultroscan XL and quantified using the Gelscan XL evaluation software (version 2.1) from Pharmacia.
Determination of Adenylyl Cyclase Activity
Adenylyl cyclase activity was determined by measuring 32 P-labeled cAMP formation from a-32 P-labeled ATP, as described previously. 47, 48 Briefly, the assay medium containing 50 mmol/L glycylglycine (pH 7.5), 0.5 mmol/L MgATP, a- The reactions were terminated after 10 minutes by the addition of 0.6 mL of 120 mmol/L zinc acetate. The cAMP was purified by coprecipitation of other nucleotides with ZnCO 3 , addition of 0.5 mL of 144 mmol/L Na 2 CO 3 , and subsequent chromatography by the double-column system, as described by Salomon.
49
Determination of Cell Proliferation
Cell proliferation was quantified by DNA synthesis, which was evaluated by incorporation of 3 H-labeled thymidine into cells, as described previously. 50 Subconfluent VSMCs from control and antisense-treated SHRs and WKY rats were plated in 6-well plates for 24 hours and were serum deprived for 24 hours to induce cell quiescence. The 3 H-labeled thymidine
(1 lCi/ml) was added and further incubated for 4 hours before the cells were harvested. The cells were rinsed twice with ice-cold PBS and incubated with 5% trichloroacetic acid for 1 hour at 4°C. After being washed twice with ice-cold water, the cells were incubated with 0.4 N sodium hydroxide solution for 30 minutes at room temperature, and radioactivity was determined using a liquid scintillation counter (Wallac 1409; Perkin Elmer Life Science). Cell viability was checked with the trypan blue exclusion technique and indicated that >90% to 95% of cells were viable.
Determination of Superoxide Anion Production and NADPH Oxidase Activity
Basal superoxide anion production and NADPH oxidase activity in heart, aorta, and kidney were measured using the lucigenin-enhanced chemiluminescence method with a low concentration (5 lmol/L) of lucigenin, as described previously. 20, 51 The heart, aorta, and kidney tissues from control and antisense-treated SHRs and WKY rats were washed in oxygenated Krebs HEPES buffer and placed in scintillation vials containing lucigenin solution, and the emitted luminescence was measured with a liquid scintillation counter (Wallac 1409; Perkin Elmer Life Science) for 5 minutes. The average luminescence value was estimated, the background value was subtracted, and the result was divided by the total weight of tissue in each sample. The NADPH oxidase activity in the samples was assessed by adding 10 to 4 mol/L NADH (Sigma-Aldrich) in the vials before counting. Basal superoxide-induced luminescence was then subtracted from the luminescence value induced by NADH.
Statistical Analysis
Data are expressed as meanAESD and were analyzed using 1-way ANOVA in conjunction with the Newman-Keuls test with GraphPad Prism 5 software (GraphPad Software). A mean difference between groups was considered statistically significant at P<0.05.
Results
Role of Liposome Quality on Antisense Transfection Efficiency
In the current study, we used freshly formulated liposomes composed of monocationic lipid DOTAP and neutral helper lipid DOPE at a 1:1-M ratio. A novel upgrade in antisense/liposomebased hypertension research was the incorporation of 10% DSPE-PEG(2000) to increase the circulation time of the liposomes. Other important factors affecting circulation time and thus transfection efficiency are size and polydispersity index. Manual extrusion was used to ensure size control and homogeneity. Liposome size was 100 to 200 nm with a polydispersity index of 0.1 measured using dynamic light scattering ( Figure 1 ). Figure 1 shows that antisense was efficiently encapsulated in liposomes, as determined using fluorescently labeled antisense (FITC). Figure 1A shows fluorescently labeled Gia-2 antisense encapsulated inside liposomes that appeared as green circles under fluorescent microscopy. Figure 1B shows measurement of the size of the PEG-cationic liposomes and the polydispersity index using dynamic light scattering. The size of the freshly formulated liposomes ranged from 100 to 200 nm with a polydispersity index of 0.1.
Effect of Gia-2 and Gia-3 Knockdown on BP and Heart Rate
To investigate the contribution of enhanced expression of Gia-2 on BP, the effect of Gia-2 knockdown on BP was examined by single intravenous injection of Gia-2 antisense into prehypertensive rats aged 3 weeks, and the results are shown in Figure 2 . Systolic BP (SBP) (Figure 2A ) was not different in SHRs aged 3 weeks compared with age-matched WKY rats and started to increase from the age of 4 weeks. Treatment of SHRs with Gia-2 antisense and not with empty liposomes or Gia-2 sense prevented the increase in SBP up to age 6 weeks (123AE2.9 mm Hg); thereafter, SBP started to increase and reached the same level as that of SHR control groups at 9 weeks (190AE5 mm Hg). A second injection of Gia-2 antisense at that time point again decreased BP significantly but not to the level in control WKY rats. In contrast, Gia-2 antisense treatment did not have any significant effect on the SBP in WKY rats (121.8AE1.6 versus 123.8AE2 mm Hg). In addition, diastolic BP ( Figure 2B ) and mean arterial BP ( Figure 2C ) were slightly higher in all SHR groups compared with WKY groups at the age of 3 weeks. The knockdown of Gia-2 protein by antisense prevented any further increase in diastolic and mean BP up to age 6 weeks; however, at age 9 weeks, like SBP, diastolic and mean arterial BPs reached the same levels as those of SHR control groups.
To investigate whether enhanced expression of Gia-3 also contributes to the development of hypertension in SHRs, the effect of Gia-3 knockdown on BP was examined using Gia-3 antisense, and the BP profile is shown in Figure 2D through 2F. SBP ( Figure 2D ), diastolic BP ( Figure 2E ), and mean arterial BP ( Figure 2F ) started to increase at the age of 4 weeks in all groups of control SHRs (SHR control, empty liposome, and Gia-3 sense group); however, BP was slightly decreased in the SHR group treated with Gia-3 antisense compared with the control SHR groups, but this decrease was not significant (mean arterial BP: control SHRs 148.5AE4.2 mm Hg; Gia-3 antisense-treated SHRs, 139.7AE4.5 mm Hg). At 9 weeks, the Gia-3 antisense-treated SHR group had the same BP as that of SHR control groups. In contrast, Gia-3 antisense treatment did not have any significant effect on the mean arterial BP in treated WKY rats (95.6AE4.9 versus 98.2AE2 mm Hg).
Both Gia-2 and Gia-3 antisense treatments did not show any adverse side effects on the health of rats because all rats treated with antisense gained weight during the study period (body weights were 142.5AE4.5 g for WKY control rats, 144AE3 g for Gia-2 antisense-treated WKY rats, 141AE5 g for Gia-3 antisense-treated WKY rats, 135AE3.5 g for control SHRs, 139.2AE3.9 g for Gia-2-antisense-treated SHRs, and 136.0AE6.0 g for Gia-3 antisense-treated SHRs). In addition, the ratio of heart weight:body weight was not different in SHRs aged 6 and 9 weeks compared with age-matched WKY rats, and it was not affected by the antisense treatment, as reported previously. Prehypertensive tachycardia has been reported in SHRs. 52, 53 To further examine the contribution of enhanced expression of Gia-2 and Gia-3 proteins to the regulation of heart rate in SHRs, the effect of antisense of Gia-2 and Gia-3 treatment on heart rate was examined in SHRs and WKY rats at age 6 and 9 weeks (Figure 3 ). At age 6 weeks ( Figure 3A ), all SHR control groups had higher heart rates than agematched WKY rats by %25%. Treatment of SHRs with Gia-2 antisense significantly attenuated increased heart rate by %15%. In contrast, Gia-3 antisense treatment did not have any significant effect on the heart rate. Furthermore, treatment of rats with empty liposomes, Gia-2 sense, and Gia-3 sense had no impact on heart rate in SHR and WKY groups. Moreover, the increased heart rate in SHRs at age 9 weeks compared with age-matched WKY rats was not attenuated by these treatments ( Figure 3B ).
Effect of Gia-2 and Gia-3 Knockdown on Gia Protein Levels in Aorta and Aortic VSMCs From SHRs and WKY Rats
To examine the relationship between BP and Gia protein expression, we determined the levels of Gia proteins by Western blotting in aortas and VSMCs from untreated control SHRs and age-matched WKY rats and those treated with different interventions at age 6 weeks, when the increase in BP was prevented by Gia-2 antisense treatment, and age 9 weeks, when BP in antisense-treated SHRs was augmented Figure 2 . Effect of Gia-2 and Gia-3 knockdown on the development of high blood pressure (BP). Antisense (AS) or sense of Gia-2 and Gia-3 encapsulated in PEG-cationic liposomes (1 mg/kg body weight) and empty liposomes were injected intravenously via tail vein once into prehypertensive spontaneously hypertensive rats (SHRs) aged 3 weeks and age-matched Wistar Kyoto (WKY) rats. A second injection of AS Gia-2 (1 mg/kg body weight) was given at 8 weeks to the AS-treated SHR group. Systolic BP (A and D), diastolic BP (B and E), and mean arterial BP (C and F) were monitored weekly using the CODA system until rats were aged 9 weeks. Values are meanAESD of 6-10 rats in each group. ***P<0.001 vs WKY control, ### P<0.001 vs SHR control. Figure 3 . A and B, Effect of Gia-2 and Gia-3 knockdown on heart rate in spontaneously hypertensive rats (SHRs) and age-matched Wistar Kyoto (WKY) rats. Antisense (AS) or sense of Gia-2 and Gia-3 encapsulated in PEG-cationic liposomes (1 mg/kg body weight) and empty liposomes were injected intravenously via tail vein once into prehypertensive SHRs aged 3 weeks and agematched WKY rats. Heart rate was monitored weekly using the CODA system. A, Effect of Gia-2 and Gia-3 AS, sense, and empty liposomes on heart rate in 6-week-old SHRs and WKY rats. B, Effect of Gia-2 and Gia-3 AS, sense, and empty liposomes on heart rate in 9-week-old SHRs and WKY rats Values are meanAESD of 6-10 rats in each group. ***P<0.001 vs WKY control (CTL), ### P<0.001 vs SHR CTL. C through F, Effect of Gia-2 and Gia-3 knockdown on the expression of Gia-2 or Gia-3 proteins in aorta and vascular smooth muscle cells (VSMCs) from SHRs aged 6 weeks and agematched WKY rats. AS or sense of Gia-2 and Gia-3 encapsulated in PEG-cationic liposomes (1 mg/ kg body weight) and empty liposomes were injected intravenously via tail vein once into prehypertensive SHRs aged 3 weeks and age-matched WKY rats. Aorta (C and D) and VSMC lysates (E and F) from 6-week-old SHRs and WKY rats with or without treatments were subjected to Western blotting using antibodies against Gia-2 (C and E) and Gia-3 (D and F). The protein bands were quantified by densitometric scanning. The results are expressed as ratio of Gi protein:dynein of WKY rats taken as 100%. Values are meanAESD of 4-6 separate experiments using different rats or cell populations in each group. **P<0.01, ***P<0.001 vs WKY CTL; ### P<0.001 vs SHR CTL.
to the same level as that of control SHRs. Results indicated that, as reported previously, 15,17 expression of Gia-2 (Figure 3C and 3E) and Gia-3 ( Figure 3D and 3F) proteins was significantly enhanced in aortas ( Figure 3C and 3D) and VSMCs ( Figure 3E and 3F) from rats aged 6 weeks by %50% to 55% in all SHR groups compared with WKY rats. In addition, the treatment of rats with Gia-2 antisense but not with sense or empty liposomes completely abolished enhanced expression of Gia-2 in aorta ( Figure 3C) ; inhibition of %70% to 80% was observed in VSMCs ( Figure 3E) . Similarly, Gia-3 antisense but not sense or empty liposomes also attenuated enhanced expression of Gia-3 protein in aortas ( Figure 3D ) and VSMCs ( Figure 3F ) from SHRs aged 6 weeks by %90% and 60%, respectively. In addition, Gia-2 and Gia-3 antisense also attenuated expression of Gia-2 and Gia-3, respectively, in aortas and VSMCs from WKY rats by %20% to 40%. In contrast, the enhanced expression of Gia-2 or Gia-3 was not attenuated by Gia-2 or Gia-3 antisense treatments in aortas from SHRs aged 9 weeks (data not shown).
Effect of Gia-2 and Gia-3 Knockdown on the Expression of Gia Proteins in Hearts and Kidney From SHRs and WKY Rats
To examine the relationship between heart rate and levels of Gia proteins, we determined the levels of Gia-2 and Gia-3 in hearts from SHRs and WKY rats with and without antisense treatment ( Figure 4) . As reported previously, 15,17 the expression of Gia-2 ( Figure 4A ) and Gia-3 ( Figure 4B ) was significantly enhanced by 75% and 55%, respectively, in hearts from SHRs compared with WKY rats. In addition, antisense of both Gia-2 and Gia-3 restored the enhanced expression of Gia-2 and Gia-3 proteins, respectively, to levels in WKY controls. Gia-2 and Gia-3 antisense also attenuated the expression of Gia-2 and Gia-3, respectively, in hearts from WKY rats by %50% and 25%, respectively. In contrast, levels of Gia-2 ( Figure 4C ) and Gia-3 ( Figure 4D ) proteins that were significantly enhanced by %50% in hearts from SHRs aged 9 weeks compared with WKY rats were not attenuated by Gia-2 or Gia-3 antisense treatments. These results suggested a role of enhanced levels of Gia-2 but not Gia-3 protein in increased heart rate in SHRs. In kidneys from SHRs and WKY rats, we examined the effect of Gia-2 and Gia-3 antisense on the expression of Gia-2 and Gia-3 proteins, respectively, which were shown to play an important role in the regulation of renal vascular tone in SHRs. 27, 54 Results shown in Figure 4 indicated that the expression of Gia-2 ( Figure 4E ) and Gia-3 ( Figure 4F ) proteins in kidneys from SHRs was significantly augmented by %40% compared with WKY rats, and this increase was completely restored to levels in WKY rats by antisense treatment. In addition, Gia-2 and Gia-3 antisense also attenuated the expression of Gia-2 and Gia-3, respectively, in kidneys from WKY rats by %25%.
Effect of Gia-2 Knockdown on Gia-3 Expression and Vice Versa
To examine the specificity of the antisense oligonucleotides, the effect of Gia-2 antisense treatment on Gia-3 protein expression and the effect of Gia-3 antisense treatment on Gia-2 protein expression was assessed in the hearts ( Figure 5A and 5B) and aortas ( Figure 5C and 5D ) from SHRs aged 6 weeks and age-matched WKY rats. Enhanced expression of Gia-2 was not attenuated by the antisense of Gia-3 ( Figure 5A and 5C), and enhanced expression of Gia-3 was not attenuated by the antisense of Gia-2 ( Figure 5B and 5D ). In addition, the antisense of Gia-3 and Gia-2 was also ineffective in attenuating the expression of Gia-2 and Gia-3 proteins, respectively, in hearts and aortas from WKY rats.
Effect of Gia-2 and Gia-3 Knockdown on Adenylyl Cyclase Inhibition in Hearts From SHRs and WKY Rats
To investigate whether knockdown of Gia-2 and Gia-3 by antisense treatment was reflected in attenuation of Gi-mediated functions, we examined the effect of antisense treatment on the inhibitory effects of oxotremorine, which interacts with muscarinic receptors coupled to adenylyl cyclase inhibition through Gia proteins. 55 Results shown in Figure 6 indicated that oxotremorine inhibited adenylyl cyclase activity in hearts from SHRs and WKY rats aged 6 weeks; however, as reported previously, 32 the extent of inhibition was significantly greater in SHRs. Oxotremorine, for example, inhibited adenylyl cyclase activity by %30% in WKY rats and %45%, in SHRs. Knockdown of Gia-2 by Gia-2 antisense attenuated oxotremorine-mediated inhibition of adenylyl cyclase by %55% (13.5+4.9% versus 29+2.0%) in WKY rats and %35% (28.0+2.8% versus 43.7%) in SHRs. In contrast, the knockdown of Gia-3 by Gia-3 antisense did not have any effect on the percentage of inhibition of adenylyl cyclase by oxotremorine in SHRs and WKY rats (29.0+2.0% versus 28.5+1.0% in WKY rats and 43.7+1.5% versus 41.7+3.8% in SHRs).
Effect of Gia-2 and Gia-3 Knockdown on Proliferation of VSMCs From SHRs and WKY Rats
Because enhanced expression of Gia proteins is implicated in hyperproliferation of VSMCs from SHRs, 56 it was of interest to examine whether knocking down of Gia proteins by antisense treatment would also result in attenuation of hyperproliferation of VSMCs from SHRs. Results shown in Figure 7 indicated that the proliferation of VSMCs from SHRs was significantly augmented by %170% compared with WKY rats, and Gia-2 and Gia-3 antisense treatment decreased hyperproliferation by %70% and 20%, respectively. In addition, the Figure 4 . Effect of Gia-2 and Gia-3 knockdown on the expression of Gia-2 or Gia-3 proteins in hearts from 6-or 9 week-old and in kidney from spontaneously hypertensive rats (SHRs) aged 6 weeks and agematched Wistar Kyoto (WKY) rats. Proteins in heart membrane (30 lg) from SHRs aged 6 weeks (A and B) and 9 weeks (C and D) and in kidney (E and F) from 6-week-old SHRs and WKY rats with or without treatment were subjected to Western blotting using antibodies against Gia-2 (A, C, and E) and Gia-3 (B, D, and F). The protein bands were quantified by densitometric scanning. The results are expressed as the ratio of Gi protein:dynein of WKY rats taken as 100%. Values are meanAESD of 4-6 separate experiments using different rats from each group. *P<0.05, **P<0.01, ***P<0.001vs WKY control (CTL); ### P<0.001 vs SHR CTL.
proliferation of VSMCs from WKY rats was attenuated significantly by both Gia-2 and Gia-3 antisense treatments.
Effect of Gia-2 Knockdown on the Production of Superoxide Anion and NADPH Oxidase Activity in SHRs Aged 6 Weeks and Age-Matched WKY Rats
Oxidative stress caused by the overproduction of reactive oxygen species contributes to the pathophysiology of cardiovascular diseases including hypertension. 57, 58 We previously reported the implication of enhanced expression of Gia proteins in enhanced oxidative stress exhibited by VSMCs from SHRs. 51 To investigate whether knockdown of enhanced levels of Gia-2 and Gia-3 proteins in SHRs by antisense treatments also resulted in attenuation of oxidative stress, the effect of antisense treatments on superoxide anion and NADPH oxidative activity was examined in hearts, aortas, and kidneys from SHRs aged 6 weeks and age-matched WKY rats ( Figure 8 ). As reported previously, 12, 20, 51 the production of superoxide anion that was increased by about %35%, 25%, and 45% in hearts, aortas, and kidneys, respectively, from SHRs compared with WKY rats ( Figure 8A through 8C) was significantly attenuated by Gia-2 and Gia-3 antisense treatment. In addition, NADPH oxidase activity was also significantly enhanced by %70%, 100%, and 45% in hearts, aortas, and kidneys, respectively, from SHRs compared with WKY rats ( Figure 8D through 8F) , and Gia-2 and Gia-3 antisense treatments almost completely restored the enhanced activity to levels in WKY controls. In contrast, Gia-2 and Gia-3 antisense decreased the production of superoxide anion and NADPH oxidase activity in these tissues from WKY rats.
Discussion
We previously showed that enhanced expression of Gia proteins may be the contributing factor in the pathogenesis of hypertension in SHRs. [15] [16] [17] [18] [19] [20] [21] This finding was supported by our study showing that the intraperitoneal injection of pertussis toxin, which inactivates both Gia-2 and Gia-3, in prehypertensive SHRs aged 2 weeks attenuated the development of high BP. 32 Furthermore, we showed recently that treatment of SHRs with natriureic peptide receptor C agonist Figure 5 . Effect of knockdown of Gia-2 antisense (AS) on the expression of Gia-3 protein and vice versa.
Heart (A and B) and aorta (C and D) from spontaneously hypertensive rats (SHRs) aged 9 weeks and agematched Wistar Kyoto (WKY) rats with or without treatment were subjected to Western blotting using antibodies against Gia-2 (A and C) and Gia-3 (B and D). The protein bands were quantified by densitometric scanning. The results are expressed as the ratio of Gi protein:dynein of WKY rats taken as 100%. Values are meanAESEM of 4 separate experiments using different rats from each group. ***P<0.001 vs WKY control (CTL).
C-ANP [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] , which inhibits the enhanced expression of both Gia-2 and Gia-3 proteins in VSMCs from SHRs, 12, 59 attenuated the development of hypertension. 12 Several studies using knockout mice have shown a role of Gia-2 in physiological functions. [60] [61] [62] [63] [64] [65] Nagata et al showed that ablation of Gia-2 in mice resulted in attenuation of muscarinic M2 receptor-mediated antiadrenergic effect on b-adrenergic receptor-induced contractility and calcium currents in adult cardiomyocytes. 64 The disruption of the Gia-2 gene in mice was also shown to result in impaired platelet activation and aggregation, 61 ulcerative colitis, and adrenocarcinoma of the colon. 65 Furthermore, a lack of Gia-2 proteins has been shown to result in dilated cardiomyopathy and increased mortality in b1-adrenoceptor-overexpressing mice 62 and in increased infarct size in the heart in myocardial ischemia reperfusion injury. 63 In addition, transgenic mice overexpressing Gi inhibitor peptide, which causes functional knockout of cardiac Gia-2 signaling when subjected to ischemia reperfusion, were shown to have increased infarct size. 60 In the present study, by using antisense oligodeoxynucleotide encapsulated in PEG-cationic liposomes to knock down the Gia-2 and Gia-3 proteins in SHRs, we reported for the first time that enhanced expression of Gia-2 and not Gia-3 plays a major role in the development of hypertension.
We found that treatment of prehypertensive SHRs aged 3 weeks with a single intravenous injection of 1 mg/kg body weight of Gia-2 antisense prevented the development of hypertension up to age 6 weeks and was associated with attenuation of enhanced expression of Gia-2 protein, which has been implicated as a contributing factor in the pathogenesis of hypertension. 15, 17 In contrast, the increase in BP at age 9 weeks may be due to the elimination of antisense from the system or to the de novo synthesis of Gi proteins. This notion was supported by our results showing that Gia-2 protein expression that was attenuated by antisense treatment in SHRs aged 6 weeks was enhanced in SHRs aged 9 weeks and was not attenuated by antisense treatment and thus contributed to increased BP. Our results are in accordance with earlier studies showing that the effect of antisense of b1-adrenoceptor on BP had worn off after 20 days. 40 In contrast, antisense treatment decreased the expression of Gia-2 proteins but not BP in WKY rats, suggesting that enhanced expression of Gia protein is implicated in the development of high BP in SHRs. Our results are consistent with our previous studies showing that pertussis toxin, which attenuated the expression of Gia proteins in WKY rats, did not affect BP. 32 We also showed that BP in all SHR groups was slightly higher compared with WKY groups at age 3 weeks. This result may be attributed to enhanced expression of Gia-2 protein and vascular changes that occur in the prehypertensive state. 31, 66, 67 Alternatively, knockdown of Gia-3 protein in SHRs using Gia-3 antisense, which decreased the enhanced levels of Gia-3 proteins, did not significantly decrease BP. It is important to note that the extent of attenuation of enhanced expression of Gia-2 and Gia-3 proteins by Gia-2 and Gia-3 antisense treatment, respectively, was almost the same, whereas high BP was decreased by knocking down only Gia-2 and not Gia-3 proteins. This result suggests the contribution of enhanced expression of Gia-2 protein to the development of hypertension. Several studies have shown that knocking out one isoform of Gia protein upregulates the expression of other isoforms of Gia protein in knockout mice. 62, 68 In the current study, however, the effect of antisense was very specific because Gia-2 antisense attenuated the expression of the Gia-2 protein without affecting the expression of Gia-3 protein, and Gia-3 antisense attenuated the expression of Gia-3 and not Gia-2 protein. Consequently, the lack of effect of Gia-3 antisense on attenuation of high BP may not be caused by upregulation of Gia-2 and further suggests a role for enhanced expression of Gia-2 in the development of high BP in SHRs. We also reported for the first time that enhanced expression of Gia-2 protein in SHRs contributes to increased heart rate in SHRs because the knockdown of Gia-2 protein attenuated the enhanced heart rate in SHRs aged 6 weeks.
Augmented expression of Gia-3 protein did not appear to play a role in the regulation of heart rate because the knockdown of Gia-3 protein by antisense treatment was ineffective in attenuating the enhanced heart rate in SHRs. Consequently, it may be suggested that the Gia-2 protein may be a major contributor to the regulation of heart rate in SHRs. The molecular mechanism responsible for Gia-2-mediated regulation of heart rate appears to involve cAMP because knockdown of Gia-2 protein by Gia-2-antisense, which attenuated increased heart rate, also attenuated enhanced inhibition of adenylyl cyclase by the Gia-2-coupled M2 receptor agonist oxotremorine in hearts from SHRs. In this regard, several G protein-coupled receptors have been shown to regulate cardiac contractility via cAMP and the Ca 2+ pathway. [69] [70] [71] Whether Gia-2 antisense also attenuates intracellular levels of Ca 2+ needs to be investigated. Our results, however, agree with the study by Nagata et al, who showed a role for Gia-2 but not Gia-3 in the regulation of cardiac contractility and calcium currents by muscarinic receptor in adult cardiomyocytes. In the present study, we demonstrated that Gia-2 and Gia-3 antisense treatment also attenuated enhanced expression of Gia-2 and Gia-3 proteins in kidney, a target tissue involved in the regulation of BP. Because enhanced expression of Gia proteins in kidneys of SHRs has been shown to contribute to increased renal vascular resistance and decreased renal blood flow that results in augmentation of BP in SHRs, 27 it may be suggested that Gia-2 antisenseinduced attenuation of enhanced expression of Gia-2 proteins in kidney may also participate in attenuation of high BP in SHRs by decreasing renal vascular resistance and increasing renal blood flow.
The attenuation of high BP by knockdown of Gia-2 is also associated with inhibition of enhanced oxidative stress and hyperproliferation of VSMCs, suggesting that attenuation of oxidative stress and hyperproliferation of VSMCs may be a mechanism contributing to the attenuation of high BP and tachycardia in SHRs. In this regard, increased oxidative stress caused by overproduction of reactive oxygen species and hyperproliferation of VSMCs have been shown to contribute to the pathophysiology of cardiovascular diseases such as hypertension and atherosclerosis. 57, 58 Alternatively, knockdown of Gia-3 in SHRs by Gia-3 antisense treatment also resulted in attenuation of enhanced oxidative stress and hyperproliferation of VSMCs in SHRs. It appears, however, that inhibition of enhanced oxidative stress and hyperproliferation induced by Gia-3 antisense may not play a role in decreasing high BP in SHRs.
Perspectives
Hypertension is a multifactorial disease. The present study demonstrated an important role for Gia-2 protein in the regulation of BP. Moreover, it showed for the first time that a single intravenous injection of Gia-2 antisense, and not Gia-3 antisense, encapsulated in PEG-cationic liposomes prevents the development of high BP and attenuates tachycardia in SHRs. Based on these findings, it may be suggested that the highly specific gene therapeutic agents encapsulated in nanoliposomes targeting Gia-2 protein may have the potential for use in the treatment and/or prevention of hypertension and tachycardia.
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